Episode Details
Back to EpisodesGut microbiota exploitation by CPX-351 in AML; optimizing anti-myeloma immunity for ASCT; which pediatric ITP patients will develop lupus?
Season 7
Published 1 year, 11 months ago
Description
In this week's episode, we'll discuss gut microbiota exploitation by CPX-351 in acute myeloid leukemia. Then we'll learn about optimizing anti-myeloma immunity. New research shows that regulatory T cells suppress myeloma-specific immunity during autologous stem cell mobilization and transplantation. Finally we'll discuss among pediatric patients with ITP or other autoimmune cytopenias, which ones will go on to develop systemic lupus?
Featured Articles:
- CPX-351 exploits the gut microbiota to promote mucosal barrier function, colonization resistance, and immune homeostasis
- Regulatory T cells suppress myeloma-specific immunity during autologous stem cell mobilization and transplantation
- Antinuclear antibody–associated autoimmune cytopenia in childhood is a risk factor for systemic lupus erythematosus